Preventing post-operative recurrence
|
|
- Cecil Lloyd
- 6 years ago
- Views:
Transcription
1 Oxford Inflammatory Bowel Disease MasterClass Preventing post-operative recurrence Dr Oliver Brain Oxford
2 Disclosures Presented at IEE, Oxford 2013 AbbVie sponsored meeting
3 Talk Outline Risk factors for recurrence Diagnosis of recurrence (briefly) Evidence for recurrence prevention
4 Preventing post-op recurrence in CD An important question Goes to the heart of our understanding (or lack) of the biology of this disease Recurrence in the absence of macro or microscopic disease Why at the anastomosis? Rutgeerts P et al Gut 1984;25: Rutgeerts P et al Gastroenterology 1990;99: Olaison G et al Gut 1992;33:
5 Pre-OP Mucus DC T Cell Paneth Cell Macrophage Fibroblast
6 Post-OP Mucus DC DC Fibroblast Paneth Cell Macrophage T Cell
7 Cosnes J et al Inflamm Bowel Dis 2002;8(4):244 Crohn s phenotype over time
8 Factors that may affect recurrence Patient-related Smoking (at least doubles recurrence rate) 1,2 * Family history Genetics Disease-related Surgery-related Age of onset* Disease duration Disease location perianal disease 3 * Disease behaviour penetrating disease 4 * Granulomas Myenteric plexitis Prior resection 5 * Extensive SB resection 5,6 * Resection margins Anastomosis type Strictureplasty Laparoscopic vs open * Reliable predictors Mutable Potentially mutable Immutable 1. Reese GE et al Int J Colorectal Dis 2008;23: Ryan WR et al Am J Surg 2004;187: Hofer B et al Hepatogastoenterology 2001;48: Simillis et al Am J Gastroenterol 2008;103: Bernell O et al Br J Surg 2000;87: Welsch T et al Int J Colorectal Dis 2007;22:1043-9
9 Approach to Treatment Immediate Delayed No treatment Pros Disease behaviour modification Prevention of surgery / bowel length preservation Cons Ad hoc patient selection and?overtreatment Ltd data of disease modification Identifiable need Known outcomes in absence of treatment Limited data of disease modification No treatment risk Primum non nocere Disease will almost invariably reoccur Disease morbidity When should we stop treatment?
10 Defining Recurrence Clinical Faecal / serum markers Endoscopic Capsule endoscopy Radiological MR, CT, US, SBE Surgical
11 Defining Recurrence Clinical Symptoms, CDAI (or CRP) underestimate recurrence 1-3 Endoscopy remains the gold standard New lesions can be visualised within weeks to months Mismatch / lag between endoscopic recurrence and symptoms At 1 year 73% endoscopic vs 20% clinical 4 1. Viscido A et al Ital J Gastroenterol Hepatol 1999;31: Regueiro et al Gastroenterology 2009;136: e1. 3.Walters TD et al Inflamm Bowel Dis 2011;17: Rutgeerts P et al Gut 1984;25:
12 Crohn s disease recurrence - Endoscopic Rutgeerts score 1 : i0 i1 i2 i3 i4 No lesions 5 apthous lesions >5, skip lesions, anastomotic lesions Diffuse apthous ileitis Diffuse with larger ulcers +/- narrowing Score POR risk 0-1 <10% at 10 yr 2 40% risk at 5 yr % risk at 5 yr 1. Rutgeerts P et al Gut 1984;25:
13 Crohn s disease recurrence - Surgical The problem: 80% patients with Crohn s disease require at least one resection 1 Surgery rates did not decline significantly in immunomodulator era 2 A small number of patients with CD develop short bowel syndrome 70% patients with CD require >1 resection over lifetime % surgical recurrence in 5 years 6 1. Caprili R et al Gut 2006;55(suppl 1):i Cosnes J et al Gut 2005;54: Chardavoyne et ak Dis Colon Rectum 1986;29: Lock et al NEJM 1981;304: Landsend E et al Sand J Gastroenterol 2006;41: Peyrin-Biroulet L et al Am J Gastroenterol 2010;105:
14 Medical therapies trialed Antibiotics 5 ASA compounds Steroids Enteral nutrition Probiotics Immunomodulators Anti-TNF agents Other biologics
15 Imidazole Antibiotics RCT metronidazole 20mg/kg/day vs placebo for 3 months 1 RCT ornidazole 1g/day vs placebo for 1 year 2 1 yr endoscopic recurrence RR 0.44 (95% CI ) 3 1 yr clinical recurrence RR 0.23 (95% CI ) 3 NNT 4 But: Effect sustained only to 1 year Higher rates adverse events RR 2.39 (95 CI ) and withdrawal 1. D Haens GR et al Gastroenterology 2008;135: Rutgeerts P et al Gastroenterology 2005;128: Doherty GA et al Aliment Pharmacol Ther 2010;31:
16 Budesonide Two placebo-controlled trials of 3mg and 6mg / day 1,2 At 1 year post-op no improvement in: Endoscopic recurrence Clinical recurrence In addition: ½ patients on steroids post-op develop dependence or resistance at 1 year 3 1.Ewe K et al Eur J Gast Hep 1999;11: Hellers G et al Gastroenterology 1999;116: Irving PM et al Aliment Pharmacol Ther 2007;26:
17 5-ASA compounds Mesalazine 3 x Meta-analyses: Reduced post-op recurrence by 13% 1 No more effective than placebo 2 Decreased clinical but not endoscopic recurrence, and inferior to Aza/ 6-MP 3 Cochrane review 4 NNT 12 to prevent clinical recurrence Sulfasalazine No benefit demonstrated 4 1.Camma et al Gastroenterology 1997;113: Ford AC et al Am J Gastroenterol 2011;106: Doherty GA et al Gastroenterology 2009; Doherty G et al Cochrane Data Sys Rev 2009:CD006873
18 Enteral Nutrition Evaluated in a single prospective non-randomised study 1 40 pts, post-op ileal / ileo-caecal CD 20 pts self-administered nocturnal NG enteral feed At 1 year: Control Enteral nutrition P value Clinical recurrence 35% 5% Endoscopic recurrence 70% 30% Unlikely to be widely applicable 1. Yamamoto T et al Aliment Pharmacol Ther 2007;25:67-72
19 Probiotics Insufficient evidence of efficacy Studies of: Lactobacillus johnsonii 1,2 Lactobacillus rhamnosus strain GG 3 Synbiotic VSL3 5 Metanalysis found probiotics ineffective to prevent endoscopic or clinical recurrence 6 1. Marteau P et al Gut 2006;55: Van Gossum A et al Inflamm Bowel Dis 2007;13: Prantera C et al Gut 2002;51: Chermesh I et al Dig Dis Sci 2007;52: Madsen K et al Gastroenterology 2008; Doherty GA et al Aliment Pharmacol Ther 2010;31:
20 Recombinant IL-10 One placebo-controlled trial 1 Tenovil given in 2 different regimens 37 Tenovil and 21 placebo patients had colonoscopy At 12 weeks post-op no difference in: Endoscopic recurrence Clinical recurrence 1. Colombel JF et al Gut 2001;49:42-46
21 Thiopurines Inflammation Meta-analysis 1 (inc 4 RCTs) Thiopurines more effective than control (placebo, antibiotics, 5ASA) at: 2 years: mean difference 13% (95% CI 2-24%); NNT 8 (clinical) 1 year: Prevents recurrence Rutgeerts i2-i4, but not severe i3-i4 Thiopurines more effective than placebo at: 1 year: mean difference 23% (95% CI 9-37%); NNT 4 (endoscopic) 1. Peyrin-Biroulet L et al Am J Gastroenterol 2009;104: Ardizzone et al Gastroenterology 2004;127:
22 Thiopurines Further Surgery Retrospective review of 326 pts 1 46 pts required reoperation > 3 years thiopurine 27% reoperation rate < 3 months thiopurine 55% reoperation rate (p<0.004) Papay P et al Am J Gastroenterol 2010;105:1158
23 Anti-TNFs and Post-Op CD Assumptions we might make: Early instigation of treatment is better 1-4 Anti-TNF can maintain remission 5 (in responders) Dual immunosuppression is better 6,7 We use anti-tnf in those with more severe disease 8 We can prevent further surgery Longer duration of treatment is better 1. Hanauer S et al Lancet 2002;359: Hymas J et al Gastroenterology 2007;132: Peyrin-Biroulet L et al Gastroenterology 2008;135: Colombel J-F et al Gastroenterology 2007;132: Behm BW et al Cochrane Rev D Haens G et al Lancet 2008;371: Colombel et al
24 D Haens G et al Lancet 2008;371:660-7 Early dual immunosuppression
25 Infliximab Preventative Strategy One published RCT 1 24 pts to IFX or placebo immediately post-op IFX group: *more smokers 46% vs 8% *fewer immunomodulators 36% vs 54% At 1 year endo recurrence (i2-i4): Placebo Infliximab 11/13 (85%) 1/11 (9%) Other prospective open label trials 2-4 are small (total 33 IFX treated patients), but are largely reflective of this response 1. Regueiro et al Gastroenterology 2009;136: Sorrentino et al 2007 Arch Intern Med 2007;167: Sakuraba et al Int J Colorectal Dis 2012;27: Yoshida et al Inflamm Bowel Dis 2012;18:1617
26 Adalimumab Preventative Strategy Small prospective studies Study Control Patients Follow-up Outcome Response Rates 1 NA 8 2 yr Endoscopic remission 2 NA 29 (high risk) 1 yr Endoscopic remission 75% 79% High risk = 2 or more of: smokers, penetrating disease, extensive resection, 2 resections Overall similar response rates to Infliximab 1. Papamichael et al J Crohn s Colitis 2012;6: Aguas et al World J Gastroenterol 2012;18:
27 Anti-TNF agents Reactive strategy St u d y Drug Control Patie nts 1 Ifx 5ASA or Aza Time since surgery Follow-up Outcome Response rates 8 6 months 6 months Mucosal healing 38% 2 Ifx NA 6 1 year 1 year Endoscopic remission 50% 3 Ifx 5ASA 13 6 months 1 year Endoscopic remission 54% 4 Ifx or Ada NA months NA Mucosal healing 50% 5 Ada NA 15 6 months 2 years Endoscopic remission 60% 1. Yamamoto et al Regueiro et al Sorrentino et al Boueyre et al Papamichal et al 2012.
28 Anti-TNF agents Reactive strategy St u d y Drug Control Patie nts 1 Ifx 5ASA or Aza Time since surgery Follow-up Outcome Response rates 8 6 months 6 months Mucosal healing 38% 2 Ifx NA 6 1 year 1 year Endoscopic remission 50% 3 Ifx 5ASA 13 6 months 1 year Endoscopic remission 54% 4 Ifx or Ada NA months NA Mucosal healing 50% 5 Ada NA 15 6 months 2 years Endoscopic remission 60% 1. Yamamoto et al Regueiro et al Sorrentino et al Boueyre et al Papamichal et al 2012.
29 Anti-TNF High risk phenotype 11 patients with multiple operations ( 2). Median 4. 3 smokers, 9 perianal disease, 9 previous 6-MP IFX 5mg/kg started 2-4 weeks post-op, not randomised Clinical remission at 2 years: 60% Endoscopic remission at 2 years: 40% Sakuraba et al Int J Colorectal Dis 2012;27:947.
30 Anti-TNF or Thiopurine? -High risk pts Open-label pilot. Prospective, randomised patients high risk, post-ileocaecal resection After 1 year: Endoscopic recurrence Histological recurrence (severe) Infliximab Azathioprine P value 9% 40% % 80% High risk = 2 or more of: age < 30 at diagnosis; penetrating disease; previous surgery. 1. Armuzzi et al JCC 2013 (Epub)
31 Anti-TNF Preventing further surgery? Pair-matched study 100 post-op patients who received IFX Matched by gender, Vienna classification, age at operation Median follow-up: IFX Control 36 months 51 months Surgical recurrence: IFX Control 3/100 34/100 HR 0.22 (95% CI ) Araki T et al Surg Today 2013 Mar 6 (Epub)
32 How long should we treat? Small study, not controlled 1 12 patients in endoscopic and clinical remission after 3 years IFX therapy (post-op) Re-scoped 4 months later 10/12 (83%) developed endoscopic recurrence Re-introduction IFX at 3mg/kg restored response 1. Sorentino et al Clin Gastroenterol Hepatol 2010;8:
33 Summary 1 Effective Therapies 5 ASA minimal efficacy Imidazole antibiotics Enteral nutrition } Tolerance problems / not widely applicable Thiopurines Most effective of non-biologic therapies Anti-TNF most effective, and?better if used early No data on dual immunosuppression in this setting
34 Summary 2 General Approach Start with a good surgeon Individualised approach Consider risk factors for severe disease Bowel length preservation Stop smoking Endoscopic follow-up 6-12 months No medication for low risk disease, colonoscopy 6-12 months Thiopurines for moderate risk disease / i2-?i3 disease Anti-TNF +/- thiopurines high risk disease / i3-4 disease
35 Examples of my approach Patient 1 Patient 2 Patient 3 26 yr old man 1 st presentation. Smoker Stenosing isolated TI disease. Ileo-caecal resection Stops smoking post-op 28 yr old woman CD diagnosed age 19 Non-smoker Age 21 Rt hemicolectomy for ileocaecal disease (stenosis) 5ASA 1 year post-op Ileal resection (stenosis) 34 yr old man CD diagnosed 29 Non-smoker Appendectomy age 27 Azathioprine for 4 years 30cm TI resection plus 6 SB strictureplasties At resection has enteroenteric fistula No treatment Colonoscopy 6 months Thiopurine Colonoscope 6-12 months Anti-TNF +/- thiopurine Colonoscope and MRI SB at 6-12 months year
Positioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationCrohn s Disease: A New Approach to an Old Problem
Management of Postoperative Crohn s Disease: A New Approach to an Old Problem Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationTrials in Prevention of Post Surgical Recurrence in Crohn s Disease
Send Orders of Reprints at reprints@benthamscience.org Reviews on Recent Clinical Trials, 2012, 7, 00-00 1 Trials in Prevention of Post Surgical Recurrence in Crohn s Disease Claudio Papi*, Federica Fascì
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationINFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationPrevention and Management of Postoperative Crohn s disease
Prevention and Management of Postoperative Crohn s disease Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center Director, Gastroenterology,
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More information5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationApproximately 80% of patients with Crohn s disease
CLINICAL REVIEW Postoperative Recurrent Luminal Crohn s Disease: A Systematic Review Peter De Cruz, MD, Michael A. Kamm, PhD, Lani Prideaux, MD, Patrick B. Allen, MD, and Paul V. Desmond, MD Abstract:
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationPrevention of Postoperative Crohn s disease
The Natural Course of postop CD Prevention of Postoperative Crohn s disease is clinically silent initially Miguel Regueiro, M.D. Professor of Medicine & Translational Research Associate Chief, Education
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationAnus,Rectum and Colon
JOURNAL OF THE Anus,Rectum and Colon http://journal-arc.jp ORIGINAL RESEARCH ARTICLE Risk factors for recurrence of Crohn s disease requiring surgery in patients receiving post-operative anti-tumor necrosis
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationAzienda Ospedaliera S. Camillo Forlanini. Unità Operativa di Gastroenterologia. Moscow June Cosimo Prantera
/ Azienda Ospedaliera S. Camillo Forlanini Unità Operativa di Gastroenterologia Moscow June 2006 Cosimo Prantera ANTIBIOTICS AND BACTERIAL SPECIES Metronidazole Bacteroides - Clostridia Ciprofloxacin Escherichia
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationOp#mizing)Management)in)IBD:) Mucosal)Healing)
Op#mizing)Management)in)IBD:) Mucosal)Healing) Vipul&Jairath&MD&PhD& Associate&Professor&of&Medicine,&Epidemiology&and& Biosta=s=cs& Western&University&&& Division&of&Gastroenterology,&& London&Health&Sciences&Network&
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationWithdrawal of drug therapy in patients with quiescent Crohn s disease
Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationPredictors of recurrence of Crohn s disease after ileocolectomy: A review
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i39.14393 World J Gastroenterol 2014 October 21; 20(39): 14393-14406 ISSN 1007-9327
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationImpact of endoscopic monitoring in postoperative Crohn s disease patients already receiving pharmacological prevention of recurrence
1130-0108/2015/107/10/586-590 Revista Española de Enfermedades Digestivas Copyright 2015 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid Vol. 107, N.º 10, pp. 586-590, 2015 ORIGINAL PAPERS Impact of endoscopic
More informationPD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc. Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Konservative Behandlungsmöglichkeiten?
PD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Fisteln bei M. Crohn : Konservative Behandlungsmöglichkeiten? INTERDISZIPLINÄRE VISZERALE CHIRURGIE
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More informationMedical Management of Intestinal Strictures
Medical Management of Intestinal Strictures Subrata Ghosh, FRCP, FRCPE, FRCPC, AGAF, FCAHS Professor of Translational Medicine Director of the Institute of Translational Medicine University of Birmingham,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationJoin the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
More informationEpidemiology / Morbidity
Perianal Crohn s Disease: Current Treatment Approach David A Schwartz, MD Director, Inflammatory Bowel Disease Center Vanderbilt University Medical Center Epidemiology / Morbidity Hellers et al, Gut 1980
More informationClinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152
Crohn's disease: management Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationCrohn s disease is a chronic inflammatory condition without a
Risk Stratification for Prevention of Recurrence of Postoperative Crohn s Disease Shirley Cohen-Mekelburg, MD, Yecheskel Schneider, MD, Stephanie Gold, MD, Ellen Scherl, MD, and Adam Steinlauf, MD Dr Cohen-Mekelburg
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationEffect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series
CASE REPORT Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series Kaori Fujiwara, Takuya Inoue, Naoki Yorifuji, Munetaka Iguchi, Taisuke Sakanaka, Ken Narabayashi,
More information4/16/2018. Updates in Crohn s Disease. Disclosures. Learning Objectives. Crohn s Disease is Progressive and Destructive
4/16/218 Disclosures Updates in Crohn s Disease David T. Rubin, MD Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Consultant
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationPouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board
Pouchitis and Cuffitis A bloody mess Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board Ileal-pouch anal anastomosis https://www.pennmedicine.org/for-health-care-professionals/for-physicians/physician-education-and-resources/clinicalbriefings/2018/february/total-proctocolectomy-with-jpouch-reconstruction-for-ulcerative-colitis
More informationAdalimumab versus infliximab in treating post-operative recurrence of Crohn s disease: a national cohort study
1130-0108/2016/108/10/642-647 Revista Española de Enfermedades Digestivas Copyright 2016. SEPD y ARÁN EDICIONES, S.L. Rev Esp Enferm Dig 2016, Vol. 108, N.º 10, pp. 642-647 ORIGINAL PAPERS Adalimumab versus
More informationCrohn s Disease. Resident Lecture 1/17/19
Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationChallenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence
Challenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence Sharon Dudley-Brown, PHD, FNP-BC, FAAN Assistant Professor Johns Hopkins University Baltimore, MD sdudley2@jhmi.edu Disclosures
More informationSafety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease
Safety and Efficacy of Endoscopic Dilatation of Strictures in Crohn s Disease Vinna An, Ashwinna Asairinachan, Michael Johnston, James Keck, Paul Salama, Steven Brown, Rodney Woods Department of Colorectal
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationCancer Risk with IBD Therapies How to Discuss with your Patients?
Cancer Risk with IBD Therapies How to Discuss with your Patients? Douglas L Nguyen, MD Assistant Clinical Professor of Medicine University of California, Irvine Medical Center H.H. Chao Comprehensive Digestive
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationOxford Inflammatory Bowel Disease MasterClass. What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France
Oxford Inflammatory Bowel Disease MasterClass What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France Disclosures Consulting and/or lecture fees from Merck, Abbott,
More informationIl ruolo degli anticorpi anti farmaco nella pratica clinica
Il ruolo degli anticorpi anti farmaco nella pratica clinica Daniela Pugliese, MD IBD Unit Complesso Integrato Columbus Gemelli Hospital Catholic University Foundation, Rome - Italy Therapeutic Drug monitoring
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationNutrition as primary therapy in IBD. Dr Clare Donnellan Leeds General Infirmary
Nutrition as primary therapy in IBD Dr Clare Donnellan Leeds General Infirmary Case GB 34 year old female Diagnosed with Crohn s in 2002? Extent Offered steroids or surgery Declined both GB Represented
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationCrohn disease (CD) is a chronic disease with clinical and
SOCIETY PAPER NASPGHAN Clinical Report on Postoperative Recurrence in Pediatric Crohn Disease Judy B. Splawski, y Marian D. Pffefferkorn, z Marc E. Schaefer, Andrew S. Day, jj Oliver S. Soldes, jj Todd
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Annals of Gastroenterology (2014) 27, 1-5 Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first real-life experience in
More informationThe future of IBD therapeutic research
The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationUntil the late 1990s, treatment of Crohn s disease was primarily aimed at
CHALLENGES IN CROHN S DISEASE An Historical Overview of the Treatment of Crohn s Disease: Why Do We Need Biological Therapies? Paul J. Rutgeerts, MD, PhD, FRCP Faculty of Medicine, Gastroenterology Section,
More informationPregnancy in IBD CDDW 2014
Pregnancy in IBD CDDW 2014 Brian Bressler MD, MS, FRCPC Director, Advanced IBD Training Program Clinical Assistant Professor of Medicine Division of Gastroenterology University of British Columbia Bressler
More informationIBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that
More informationMeta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn s Disease
GASTROENTEROLOGY 2008;135:1500 1509 Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn s Disease SARA RENNA,* CALOGERO CAMMÀ,, IRENE MODESTO,*
More informationWHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?
WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY? Siew Ng, Professor MBBS, FRCP, (Lon, Edin), PhD (Lond), AGAF, FHKCP, FHKAM (medicine) Department of Medicine and Therapeutics Chinese University
More informationActivity and Endoscopic measures : Crohn s disease. Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York
Activity and Endoscopic measures : Crohn s disease Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York J-F Colombel has served as consultant or advisory board member
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More information11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery
Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More information